vs

Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $20.3M, roughly 1.0× Ispire Technology Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -66.3%, a 33.8% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -51.5%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -17.8%).

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

ISPR vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.0× larger
LUNG
$20.6M
$20.3M
ISPR
Growing faster (revenue YoY)
LUNG
LUNG
+42.8% gap
LUNG
-8.7%
-51.5%
ISPR
Higher net margin
ISPR
ISPR
33.8% more per $
ISPR
-32.5%
-66.3%
LUNG
Faster 2-yr revenue CAGR
LUNG
LUNG
Annualised
LUNG
-0.5%
-17.8%
ISPR

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
ISPR
ISPR
LUNG
LUNG
Revenue
$20.3M
$20.6M
Net Profit
$-6.6M
$-13.7M
Gross Margin
17.1%
77.9%
Operating Margin
-33.9%
-40.9%
Net Margin
-32.5%
-66.3%
Revenue YoY
-51.5%
-8.7%
Net Profit YoY
17.4%
5.5%
EPS (diluted)
$-0.12
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISPR
ISPR
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$20.3M
$22.6M
Q3 25
$30.4M
$21.5M
Q2 25
$20.1M
$23.9M
Q1 25
$26.2M
$22.5M
Q4 24
$41.8M
$23.8M
Q3 24
$39.3M
$20.4M
Q2 24
$37.3M
$20.8M
Net Profit
ISPR
ISPR
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-6.6M
$-10.4M
Q3 25
$-3.3M
$-14.0M
Q2 25
$-14.8M
$-15.2M
Q1 25
$-10.9M
$-14.4M
Q4 24
$-8.0M
$-13.2M
Q3 24
$-5.6M
$-14.1M
Q2 24
$-3.5M
$-15.3M
Gross Margin
ISPR
ISPR
LUNG
LUNG
Q1 26
77.9%
Q4 25
17.1%
77.6%
Q3 25
17.0%
74.7%
Q2 25
12.3%
72.1%
Q1 25
18.2%
72.5%
Q4 24
18.5%
74.0%
Q3 24
19.5%
73.7%
Q2 24
28.3%
73.7%
Operating Margin
ISPR
ISPR
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-33.9%
-43.8%
Q3 25
-8.9%
-66.9%
Q2 25
-72.7%
-62.0%
Q1 25
-40.4%
-64.6%
Q4 24
-17.6%
-56.5%
Q3 24
-13.4%
-69.3%
Q2 24
-9.2%
-75.2%
Net Margin
ISPR
ISPR
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-32.5%
-46.1%
Q3 25
-10.7%
-64.9%
Q2 25
-73.4%
-63.6%
Q1 25
-41.5%
-64.1%
Q4 24
-19.1%
-55.4%
Q3 24
-14.2%
-69.4%
Q2 24
-9.4%
-73.7%
EPS (diluted)
ISPR
ISPR
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.12
$-0.25
Q3 25
$-0.06
$-0.34
Q2 25
$-0.26
$-0.38
Q1 25
$-0.19
$-0.36
Q4 24
$-0.14
$-0.33
Q3 24
$-0.10
$-0.36
Q2 24
$-0.07
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISPR
ISPR
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$17.6M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$-7.7M
$45.8M
Total Assets
$84.4M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISPR
ISPR
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$17.6M
$69.8M
Q3 25
$22.7M
$76.5M
Q2 25
$24.4M
$75.5M
Q1 25
$23.5M
$74.6M
Q4 24
$34.4M
$70.9M
Q3 24
$37.7M
$63.3M
Q2 24
$35.1M
$63.5M
Total Debt
ISPR
ISPR
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
ISPR
ISPR
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$-7.7M
$54.1M
Q3 25
$-1.8M
$60.0M
Q2 25
$604.7K
$69.1M
Q1 25
$14.8M
$77.7M
Q4 24
$24.2M
$85.8M
Q3 24
$30.7M
$93.9M
Q2 24
$34.5M
$101.2M
Total Assets
ISPR
ISPR
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$84.4M
$129.3M
Q3 25
$96.4M
$138.3M
Q2 25
$102.2M
$147.2M
Q1 25
$115.7M
$150.7M
Q4 24
$132.0M
$162.8M
Q3 24
$129.0M
$167.4M
Q2 24
$122.6M
$172.6M
Debt / Equity
ISPR
ISPR
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISPR
ISPR
LUNG
LUNG
Operating Cash FlowLast quarter
$-4.0M
Free Cash FlowOCF − Capex
$-4.0M
FCF MarginFCF / Revenue
-19.9%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISPR
ISPR
LUNG
LUNG
Q1 26
Q4 25
$-4.0M
$-7.1M
Q3 25
$-1.2M
$-8.2M
Q2 25
$4.7M
$-3.9M
Q1 25
$-12.5M
$-13.2M
Q4 24
$-3.2M
$-6.7M
Q3 24
$3.6M
$-7.2M
Q2 24
$-1.4M
$-5.8M
Free Cash Flow
ISPR
ISPR
LUNG
LUNG
Q1 26
Q4 25
$-4.0M
$-7.1M
Q3 25
$-1.2M
$-8.3M
Q2 25
$3.7M
$-4.0M
Q1 25
$-12.7M
$-13.5M
Q4 24
$-3.2M
$-6.8M
Q3 24
$3.3M
$-7.7M
Q2 24
$-2.2M
$-6.2M
FCF Margin
ISPR
ISPR
LUNG
LUNG
Q1 26
Q4 25
-19.9%
-31.4%
Q3 25
-3.9%
-38.4%
Q2 25
18.6%
-16.6%
Q1 25
-48.4%
-60.0%
Q4 24
-7.7%
-28.8%
Q3 24
8.5%
-37.6%
Q2 24
-5.9%
-30.0%
Capex Intensity
ISPR
ISPR
LUNG
LUNG
Q1 26
Q4 25
0.3%
0.1%
Q3 25
0.0%
0.4%
Q2 25
4.8%
0.2%
Q1 25
0.7%
1.3%
Q4 24
0.1%
0.5%
Q3 24
0.7%
2.0%
Q2 24
2.0%
2.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons